Sun Pharma to sell AstraZeneca’s heart drug in India
Sun Pharma and AstraZeneca entered into distribution service agreement for ticagrelor drug in India
Mumbai: Sun Pharmaceutical Industries Ltd and AstraZeneca Pharma India Ltd (AZPIL) have entered into a distribution services agreement for AstraZeneca’s brand Axcer, a new brand of ticagrelor, a drug used in the treatment of acute coronary syndrome—a condition marked by decreased blood flow to the heart.
AZPIL has been selling a similar brand under the name Brilinta in India since 2012.
Sun Pharma will be promoting and distributing Axcer in India. “This collaboration enables AstraZeneca to expand usage of this molecule, through wider reach among physicians, and thereby benefit a greater number of acute coronary syndrome patients... it strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy," stated a release from Sun Pharma.
Sanjay Murdeshwar, managing director, AZPIL, said, “Ticagrelor works by preventing the formation of new blood clots and maintains blood flow in the body, helping reduce a patient’s risk of another heart attack or cardiovascular-related death."
The drug has been shown to reduce the rate of a combined end point of cardiovascular death, myocardial infarction and stroke compared to clopidogrel, said the statement.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!